| abstract |
The invention describes an isomer, enantiomer, diastereomer or tautomer of a compound represented by formula (I), in which A represents O, S, NR or CR, where R is defined in the text of the description of the invention; in the formula of the compound, either a single or a double bond is represented; R is selected from H, halogen, R, OR, SR, COOR, SON (R), N (R), CON (R), NRC (O) R or NRC (O) NR, where the values of R and each R are defined in the description; B is NR or CR, provided that one of A or B is CR or CR, where the meaning of R is defined in the description; K means N or CR, where the value of R is defined in the text of the description; L represents N or CR, where R has the same meanings as RM means N or CR, where R has the same meanings as R; Y means O or S; Z is N (R) R or OR, where R is H or alkyl, or NRR, wherein R and R are as defined herein; R 1 is alkyl, cycloalkyl, alkenyl, Het, alkylaryl, alkyl-Het; or R is such where R, R and Q are defined in the text of the description; Y is O or S; R is H, (C1-6 alkyl), (C) cycloalkyl or (C) alkyl- (C) cycloalkyl, aryl, Het, (C) alkylaryl or (C) alkyl-Het, each of which is optionally substituted with R; or R is covalently linked to either R or R to form a 5- or 6-membered heterocycle; or a salt or derivative of said compound as an inhibitor of hepatitis C virus NS-polymerase |